Ipsen licences second ADC via $1B bet on Foreseen Bio asset

Ipsen entered into an exclusive global licensing agreement with Foreseen Biotechnology potentially worth up to $1.03 billion for the latter’s clinic-ready antibody-drug conjugate (ADC) FS001. The deal marks Ipsen’s second ADC tie-up this year after bagging Sutro Biopharma’s ROR1-targeting STRO-003 for up to $900 million in April.